Before Moore, O’Malley, and Wallach. Appeal from the Eastern District of Texas (Judge Gilstrap).
Summary: Claims directed to summarizing and presenting information on display interfaces for electronic devices are patent eligible under 35 U.S.C. § 101 when they are directed to a specific improvement over prior systems rather than an abstract idea.
The PTAB has determined that a patent owner may not moot a CBM proceeding by disclaiming claims post-institution. Emerson Electric Co. v. SIPCO, LLC, CBM2016-00095, Paper 39 (P.T.A.B. Jan. 16, 2018).
Before Dyk, Schall, and Reyna. Appeal from the Patent Trial and Appeal Board.
Summary: Final written decisions by an administrative tribunal invalidating a patent can have a preclusive effect.
Before Newman, Dyk, and O’Malley. Appeal from the Patent Trial and Appeal Board.
Summary: The PTAB may enter an adverse judgment against a patent owner where, before issuing an institution decision on an IPR petition, the patent owner disclaims all challenged claims but does not request adverse judgment.
The U.S. Food and Drug Administration has announced approval of Abbott’s FreeStyle Libre flash glucose monitoring system for certain diabetes patients.
In an EPO opposition proceeding challenging several of Broad’s European patents, the EPO’s Opposition Division revoked Broad’s foundational CRISPR patent, EP2771468. This EPO decision will likely lead to the revocation of several more – but not all – of Broad’s European patents.
Before Prost, Renya, and Wallach. Appeal from the Patent Trial and Appeal Board.
Summary: A patent owner cannot retroactively bring a continuation-in-part patent within the scope of § 121 during reexamination by removing the new matter and designating it as a divisional.
The FDA may begin certifying the laboratories that produce lab-developed tests (“LDTs”) instead of drafting regulatory rules to cover the tests themselves.
Medtronic announced FDA approval and U.S. launch of its Intellis Platform for the management of certain types of chronic intractable pain.
The U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb recently announced that the agency plans to publish a draft guidance outlining a voluntary alternative pathway for new, moderate-risk devices for use in patient care.
